John Wiley & Sons

SHERPA: Green

People

  1. Zelenetz
    Zelenetz
  2. Horwitz
    Horwitz
  3. Palomba
    Palomba
  4. Yahalom
    Yahalom
  5. Moskowitz
    Moskowitz
  6. Noy
    Noy
  7. Hamlin
    Hamlin
  8. Zhang
    Zhang
  9. Perales
    Perales
  10. Giralt
    Giralt

Groups

  1. Center for Hematologic Malignancies (93)
  2. Department of Medicine (93)
  3. Hematologic Malignancies, Division of (93)
  4. Lymphoma (93)
  5. Survivorship Research (23)
  6. Population Sciences Research Program (15)
  7. Executive Committee, Center for Hematologic Malignancies (13)
  8. Biostatistics Service (11)
  9. Epidemiology and Biostatistics (11)
  10. Radiation Oncology, Department of (9)
Search Within
  1. "Lymphoma"
Formats
  1. Journal Article (49)
  2. Meeting Abstract (37)
  3. Research Letter (3)
  4. Editorial (2)
  5. Book Section (1)
  6. Review (1)
Groups
  1. Center for Hematologic Malignancies (93)
  2. Department of Medicine (93)
  3. Hematologic Malignancies, Division of (93)
  4. Lymphoma (93)
  5. Survivorship Research (23)
  6. Population Sciences Research Program (15)

More Groups

People
  1. Andrew Zelenetz (39)
  2. Craig Moskowitz (15)
  3. Steven Horwitz (15)
  4. Anas Younes (13)
  5. Maria Palomba (13)
  6. David Straus (12)

More People

Years
  1. 2024 (5)
  2. 2023 (7)
  3. 2022 (4)
  4. 2021 (6)
  5. 2020 (9)
  6. 2019 (8)

More Years

Publications
  1. British Journal of Haematology (79)
  2. Hepatology (5)
  3. Journal of Cellular Biochemistry (2)
  4. American Journal of Hematology (1)
  5. Annals of the New York Academy of Sciences (1)
  6. Evidence-Based Hematology (1)

More Publications

Results (93)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Final results of a phase II study of CHOEP plus lenalidomide as initial therapy for patients with stage II–IV peripheral T-cell lymphoma
    Journal Article

    Stuver, R.; Horwitz, S. M.; Advani, R. H.; Vose, J. M.; Lee, H. J.; Mehta-Shah, N.; Zain, J. M.; Haverkos, B.; Lechowicz, M. J.; Moskowitz, A. J.; more...
    British Journal of Haematology (2023)

    Fulltext@MSK | Save
  • Long-term outcomes of patients with limited-stage ocular adnexal DLBCL treated with combined modality therapy in the rituximab era
    Research Letter

    Qualls, D.; Imber, B. S.; Okwali, M.; Hamlin, P. A.; Kumar, A.; Lahoud, O. B.; Matasar, M. J.; Noy, A.; Owens, C.; Zelenetz, A. D.; more...
    British Journal of Haematology (2023)

    Fulltext@MSK | Save
  • Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in previously treated mantle cell lymphoma: Updated results from the phase 1/2 BRUIN study
    Meeting Abstract

    Wang, M.; Shah, N.; Alencar, A.; Gerson, J.; Patel, M.; Fakhri, B.; Jurczak, W.; Tan, X.; Lewis, K.; Fenske, T.; more...
    British Journal of Haematology (2022)

    Fulltext@MSK | Save
  • Characterization and outcomes in patients with mogamulizumab-associated skin reactions in the MAVORIC trial
    Meeting Abstract

    Musiek, A.; Whittaker, S.; Horwitz, S.; Bagot, M.; Huen, A.; Fisher, D.; Haun, P.; Vermeer, M.; Ito, T.; Dwyer, K.; more...
    British Journal of Haematology (2022)

    Fulltext@MSK | Save
  • Mosunetuzumab monotherapy is an effective and well-tolerated treatment option for patients with relapsed/refractory follicular lymphoma who have received ≥ 2 prior lines of therapy: Pivotal results from a phase I/II study
    Meeting Abstract

    Budde, E.; Sehn, L. H.; Matasar, M.; Schuster, S. J.; Assouline, S.; Giri, P.; Kuruvilla, J.; Canales, M.; Dietrich, S.; Fay, K.; more...
    British Journal of Haematology (2022)

    Fulltext@MSK | Save
  • Polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin and prednisone (pola-R-CHP) versus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) therapy in patients with previously untreated diffuse large B-cell lymphoma: Results from the phase III POLARIX study
    Meeting Abstract

    Tilly, H.; Morschhauser, F.; Sehn, L. H.; Friedberg, J. W.; Trněný, M.; Sharman, J. P.; Herbaux, C.; Burke, J. M.; Matasar, M.; Rai, S.; more...
    British Journal of Haematology (2022)

    Fulltext@MSK | Save
  • Fimepinostat (CUDC-907) in patients with relapsed/refractory diffuse large B cell and high-grade B-cell lymphoma: Report of a phase 2 trial and exploratory biomarker analyses
    Journal Article

    Landsburg, D. J.; Barta, S. K.; Ramchandren, R.; Batlevi, C.; Iyer, S.; Kelly, K.; Micallef, I. N.; Smith, S. M.; Stevens, D. A.; Alvarez, M.; more...
    British Journal of Haematology (2021)

    Fulltext@MSK | Save
  • CheckMate 436: Primary efficacy and safety analysis of the phase 2 study evaluating nivolumab combined with brentuximab vedotin for relapsed/refractory mediastinal gray zone lymphoma
    Meeting Abstract

    Santoro, A.; Moskowitz, A.; Ferrari, S.; Carlo-Stella, C.; Collins, G.; Fanale, M.; Francis, S.; Sacchi, M.; Savage, K.
    British Journal of Haematology (2021)

    Fulltext@MSK | Save
  • Pirtobrutinib (LOXO-305), a next generation highly selective non-covalent Bruton's tyrosine kinase inhibitor in previously treated mantle cell lymphoma and other non-Hodgkin lymphomas: Results from the phase 1/2 BRUIN study
    Meeting Abstract

    Eyre, T.; Shah, N. N.; Alencar, A.; Gerson, J. N.; Patel, M. R.; Fakhri, B.; Jurczak, W.; Tan, X.; Lewis, K.; Fenske, T.; more...
    British Journal of Haematology (2021)

    Fulltext@MSK | Save
  • Brentuximab vedotin plus chemotherapy for patients with previously untreated, Stage III or IV classical Hodgkin lymphoma: 5-year update of the phase 3 ECHELON-1 study (NCT01712490)
    Meeting Abstract

    Radford, J.; Dlugosz-Danecka, M.; Connors, J. M.; Illes, A.; Picardi, M.; Lech-Maranda, E.; Feldman, T.; Smolewski, P.; Savage, K. J.; Bartlett, N. L.; more...
    British Journal of Haematology (2021)

    Fulltext@MSK | Save